Actuate has a company-defining elraglusib Phase 2 pancreatic-cancer survival signal and a new oral IND, but the same source set shows no product revenue, going-concern disclosure, and a need for capital beyond July 2026.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
